Dutasteride (Avodart) Provides No Clinical Benefit to Men with Recurrent Castrate Resistant Prostate Cancer
At the University of New Mexico School of Medicine in Albuquerque, New Mexico (SKS) the Department of Urology just completed a study that showed that dutasteride, the generic name for a dual 5alpha-reductase inhibitor made by GlaxoSmithKline and marketed under the name Avodartā¢ in the US and Avolveā¢ in Europe, when administered to men with [...]
